Busulphan is used in conditioning regimens prior to SCT. A relationship between exposure to busulphan, expressed as an area under the plasma concentration time curve (AUC), and effect and/or adverse effects, such as veno-occlusive disease (VOD), was reported. Exhaustion of glutathione (GSH) contributes to VOD and modulation of intracellular levels of GSH influences bulsulphan-induced toxicity in hepatocytes. Thus, increase of GSH might serve as prophylaxis against VOD. However, it should not interfere with the myeloablative effects of busulphan. We investigated the relationship between exposure to busulphan, and its in vitro toxicity to CD34 + hematopoietic progenitors from volunteers using clonogenic assays. Busulphan inhibited colony formation by CD34
Busulphan is an alkylating agent currently used in high doses in conditioning regimens before stem cell transplantation (SCT). Pharmacokinetic investigations of busulphan have shown a linear relationship between the dose and area under the plasma concentration time curve (AUC).
1,2 However, several studies have shown a wide inter-and intrapatient variability in busulphan pharmacokinetics. Age, circadian rhythmicity, underlying diseases, drug-drug interaction and bioavailability were identified as factors underlying the wide variability. [3] [4] [5] [6] Busulphan has been shown to have a narrow therapeutic window and under-or overdosing may have a fatal outcome for the patient. Several attempts have been made to define the pharmacodynamics of busulphan, ie relation between dose/drug exposure and response or adverse effects. 4, 7, 8 In vitro studies showed a relationship between the concentration of busulphan and cytotoxicity in several cell lines; however, incubation time was frequently treated as an independent factor which makes the studies difficult to compare. [9] [10] [11] In a recent study, we have shown that busulphan induced cytotoxicity in the myeloid P39 cell line in an AUC-dependent manner, and that the relationship between AUC and effect was linear. 12 The myelotoxicity of busulphan to subsets of hematopoietic progenitors defined by their lineage commitment and differentiation stage was investigated in vitro and in vivo. These studies showed that busulphan mainly affected quiescent hematopoietic stem cells. However, the sensitivity of different lineage-committed progenitors varied considerably. [13] [14] [15] [16] [17] [18] The effect of busulphan on hematopoietic progenitors in vitro was found to be concentration-and time-dependent. 16, 18, 19 Pharmacodynamic studies in patients undergoing SCT showed a relationship between drug exposure expressed as AUC, and toxicity, such as veno-occlusive disease (VOD) and neurotoxicity. 4, 8, 20, 21 VOD is a life-threatening complication and the reported incidences vary considerably. VOD may improve spontaneously, but the mortality of severe VOD is about 20-50%. The pathophysiology of VOD is not fully understood, but low constitutive levels of glutathione (the most important intracellular antioxidant) in centrilobular hepatocytes, together with further glutathione exhaustion by cytotoxic drugs or radiation may contribute to VOD development. 22 A model of hepatic VOD was established in the rat. In this model, VOD was induced by treatment with monocrot-aline that exhausted glutathione (GSH) from sinusoidal endothelial cells. Animals treated with N-acetyl-L-cysteine were protected against monocrotaline-induced hepatic VOD as shown by less histological changes and clinical manifestation. 23 The cellular content of GSH may be modulated in vitro and in vivo by different treatments. 24 Precursors of GSH, such as methionine or N-acetyl-L-cysteine (NAC), increase the cellular content of GSH. NAC is used to treat hepatotoxicity induced by acetaminophen. 25 NAC has few and mild side-effects and is therefore a potential candidate drug for VOD prophylaxis. Recently, a case report on three patients with VOD, who were successfully treated with NAC, was published. 26 On the other hand, depletion of GSH increases the toxicity of alkylating agents in most cell systems studied. GSH may be depleted in vivo by treatment with buthionine sulfoximine and in vitro by incubation in medium without sulfur amino acids, or by treatment with buthionine sulfoximine or ethacrynic acid. 27 L-buthionine-[S,R]-sulfoximine (BSO) is an irreversible inhibitor of ␥-glutamylcysteine synthetase, an enzyme catalyzing the first step of the de novo synthesis of GSH in cells. 28 Involvement of GSH in the metabolism of busulphan has been studied in animal models and in man. [29] [30] [31] Several investigations confirmed that busulphan is metabolized in the liver through conjugation with GSH catalyzed by glutathione S-transferases (GST). The reaction is catalyzed in human liver mainly by GSTA1-1, and to a lesser degree by other isoforms, GSTM1-1 and GSTP1-1. 32, 33 Treatment with busulphan depleted GSH by 60% in murine hepatocytes in vivo and by 50% in vitro. 34 In the same study, modulation of the cellular level of GSH changed busulphan cytotoxicity to hepatocytes, in that cells depleted of GSH were more sensitive and cells with increased GSH less sensitive to the effect. Moreover, GST inhibitors prevented busulfan toxicity to hepatocytes in vitro.
The effect of modulation of GSH on busulphan-induced cytotoxicity has not been studied in hematopoietic cells. Hematopoietic stem cells do not express GSTA1, which might explain the sensitivity of these cells to busulphan. 35 However, hematopoietic cells express other GST isoforms whose activity has to be considered when cellular content of GSH is increased by N-acetylcysteine. 36 In the present study we investigated the pharmacodynamic relationship between AUC and busulphan cytotoxicity in human CD34
+ cells in vitro. The ability of busulphan to inhibit myeloid and erythroid growth was investigated with clonogenic assay. Secondly, we investigated the effect of modulation of the cellular content of GSH on busulphaninduced cytotoxicity in hematopoietic progenitors in vitro and in vivo. We found a linear relation between exposure to busulphan expressed as AUC and cytotoxicity in normal human CD34
+ hematopoietic cells in vitro. By using three parallel systems, normal human CD34 + hematopoietic progenitor cells and a myeloid cell line in vitro, and a murine model for studies in vivo, we demonstrate clear evidence that modulation of GSH content in hematopoietic cells does not counteract the hematotoxic effect of busulphan.
Volunteers, materials and methods

Bone marrow volunteers and CD34
+ cell separation
Ten healthy volunteers were recruited after a medical interview. The study followed the guidelines of the local authorities and was approved by the local ethical committee. Approximately 10-15 ml of bone marrow was aspirated under local anesthesia from the spina illiaca anterior superior, and mononuclear cells were separated by density gradient centrifugation on ficoll. CD34 + cells were separated by positive selection using a CD34 + MACs Separation Kit according to the manufacturer's instructions. Cells were incubated in RPMI-1640 medium supplemented with 10% heat inactivated fetal bovine serum at 37°C in a humidified 5% CO 2 atmosphere. Cells used for the pharmacodynamic study were incubated in busulphan at final concentrations of 1, 2.5, 5, 10, 20, 40 or 60 g/ml for 2, 4 or 8 h. Cells used for the GSH modulation part were treated with Nacetyl-L-cysteine (1 mm) or L-buthionine-[S,R]-sulfoximine (50 m) for 16 to 18 h, followed by busulphan in final concentrations of 4.5 or 10 g/ml for 4 h. After incubation, cells were washed and plated for clonogenic assay.
Materials
The following materials were used in the study: RPMI-1640, Iscove's modified Dulbecco's medium, phosphate buffered saline, penicillin/streptomycin, fetal bovine serum (Life Technologies, Täby, Sweden); MethoCult GF H4434 and MethoCult GF M3534 (Metachem Diagnostics, Piddington, UK); CD34 + Separation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany); Lymphoprep (Nycomed, Oslo, Norway); 3 H-thymidine (Amersham Pharmacia Biotech UK, Buckinghamshire, UK); cholesterol, L-␣-phosphatidylcholine and 1,2-dioleolyl-sn-glycero-3-phosphate (Avanti Polar-Lipids, Alabaster, AL, USA); natrium chloride 9 mg/ml (Fresenius Kabi, Uppsala, Sweden); glucose 50 mg/ml (Pharmacia-Upjohn, Uppsala, Sweden). Other chemicals were purchased from Sigma Chemical (St Louis, MO, USA).
Animals and treatment
Balb/c mice were purchased from B&K Universal Limited, Sollentuna, Sweden. Female mice were 6 to 12 weeks old with weights ranging from 20 to 24 g. The local animal ethical committee approved animal housing conditions and experimental design. Animals were fed with standard pelleted food and water ad libitum. Animals were treated once a day for 4 consecutive days. Treatment consisted of Nacetyl-L-cysteine (1.38 Ϯ 0.07 mmol/kg) orally or Lbuthionine-[S,R]-sulfoximine (0.93 Ϯ 0.03 mmol/kg) intraperitoneally followed by liposomal busulphan (37 Ϯ 1.4 mg/kg) intraperitoneally. Animals were killed on days 1, 3, 6, 9 or 12 after the last dose of treatment.
Cell line
The P39 cell line was kindly provided by Prof Y Yoshida (Center for South East Asian Studies, Kyoto University, Kyoto, Japan). Cells were cultured in RPMI-1640 medium supplemented with 10% heat inactivated fetal bovine serum (FBS), penicillin (25 IU/ml) and streptomycin (25 g/ml) at 37°C in a humidified 5% CO 2 atmosphere. Exponentially growing cells were used in all experiments. Cells were incubated with N-acetyl-L-cysteine (1 mm) or L-buthionine-[S,R]-sulfoximine (50 m) for 16 to 18 h and then with busulphan at final concentrations of 10, 20 or 40 g/ml for 4 h. After incubation, cells were washed and re-cultured in busulphan-free medium for 72 h.
Preparation of busulphan
Busulphan for in vitro studies was diluted in sterile dimethyl sulfoxide (DMSO) and then in medium before addition to cell suspensions. The final concentration of DMSO was 0.05% for CD34
+ cells and 0.2% for P39 cells. Liposomal busulphan was used in the in vivo study and prepared as described previously. 37 It was prepared freshly before each experiment and stored in a refrigerator.
In vitro pharmacokinetics
The concentration of busulphan at the end of the incubation was calculated as C = C 0 .e Ϫkt (half-life in RPMI-1640 medium at 37°C 16 hours, k = 0.043) and the AUC was calculated according to the trapezium rule.
Clonogenic assay
CD34
+ cells were treated with NAC, BSO, DMSO or busulphan alone or in combinations, washed and 2000 cells were plated in 1.1 ml of MethoCult GF H4434 in 35 mm Petri dishes in triplicates. Colonies were scored on day 14 using an inverted microscope. Murine bone marrow was harvested on days 1, 3, 6, 9 or 12 after the last dose of the treatment. The control group and each treatment group consisted of a minimum of three animals at each time point. Mice were killed under general anesthesia. Both femurs were removed and bone marrow was flushed out under sterile conditions. Cells were counted in Türk solution and nucleated cells (0.5 ϫ 10 5 ) were plated in 1.1 ml of MethoCult GF M3534 in 35 mm Petri dishes in triplicates. The plates were placed in an incubator (37°C, 5% CO 2 and 100% humidity). CFU-GM, consisting of 50 cells or more, were counted on the day 7 using an inverted microscope.
Proliferation, clonogenicity and apoptosis in P39 cells
Proliferation was assessed using the 3 H-thymidine incorporation assay. Clonogenic capacity was determined in 0.9% methylcellulose and apoptosis by morphology with May-Grünwald-Giemsa staining as described previously. 12 
GSH assay and protein quantification
Intracellular concentrations of glutathione were determined using an enzymatic assay according to Tietze. 38 Total cellular protein was assessed according to Lowry after dissolving the precipitate in 1 m NaOH. 39 
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Results
Pharmacodynamic effect of busulphan on CD34
+ cells
Busulphan-inhibited colony formation by CD34 + cells was AUC-dependent and linear both for CFU-GM and erythroid colonies (Figure 1a and b) . The sensitivity of CFU-GM was twice as high as the sensitivity of erythroid colonies, expressed as I-AUC 50 (AUC inhibiting colony formation by 50%) or I-AUC 100 (AUC completely inhibiting colony formation). Inhibitory concentrations are presented in Table 1 .
Modulation of GSH and its effect on busulphan-induced cytotoxicity in CD34
+ cells in vitro affect busulphan-induced inhibition of colony formation of CFU-GM or erythroid colonies. Neither did preincubation of CD34 + cells with BSO change busulphan-induced inhibition of clonogenic growth. NAC or BSO alone did not influence the colony formation of CFU-GM or erythroid colonies from CD34 + cells. Figure 2 represents the results for CFU-GM and similar results were obtained for erythroid colonies. 
Modulation of GSH and its effect on busulphan-induced cytotoxicity in the myeloid P39 cell line
assay (Figure 3). As for CD34
+ progenitors, neither NAC nor BSO influenced the effect of busulphan on the clonogenic capacity of P39 cells. However, BSO alone decreased the clonogenic capacity of P39 cells by 50% immediately at the end of incubation, but the cells fully recovered after 24 h in BSO-free media. An additive effect of BSO and busulphan in concentration of 10 g/ml was observed immediately after the end of incubation. However, no such additive effect was observed at later time points or in higher concentrations of Bu. Pretreatment of P39 cells with NAC or BSO did not change the levels of apoptosis induced by busulphan (data not shown).
Effect of treatment with GSH modulators on busulphaninduced myelosuppression in mice
Busulphan induced stable myelosuppression on days 3 to 12 as assayed with CFU-GM colony formation assay. The combination of NAC with busulphan did not significantly influence the myelosuppressive effect of busulphan. Treatment of mice with BSO and busulphan did not change the level of myelosuppression compared to animals treated with busulphan alone. Neither NAC nor BSO influenced the CFU-GM formation compared to the control group. Data are presented in Figure 4 .
Discussion
Due to the narrow therapeutic window of busulphan, and to the severe potential complications of both over-and underdosing, studies of pharmacodynamics and mechanisms of cytotoxicity are of high clinical relevance.
We investigated the pharmacodynamic effects of busulphan on CD34
+ progenitor cells in vitro. Our results showed a linear relation between the area under the AUC and inhi- Mice were treated once a day for 4 consecutive days with N-acetylcysteine or buthionine sulfoximine followed by busulphan administration. Bone marrow was harvested on days 1, 3, 6, 9 and 12 after the last dose of treatment. Nucleated cells were plated in methylcellulose medium and CFU-GM were counted on day 7. Each point represents mean Ϯ standard deviation of minimum of three animals for treatment groups and 15 animals for control group. Notreat, control animals; NAC, animals treated with NAC alone; BSO, animals treated with BSO alone; LB, animals treated with liposomal busulphan alone; NAC+LB, animals treated with NAC and liposomal busulphan; BSO+LB, animals treated with BSO and liposomal busulphan.
bition of clonogenic growth. The AUCs that completely inhibited colony formation for CFU-GM (69 Ϯ 7.5 g.h/ml) and for erythroid colonies (140 Ϯ 36 g.h/ml) are in agreement with the cumulative AUC (AUC single dose ϫ number of dose) of busulphan during conditioning regimens before SCT calculated from our own data and other reports. 8, 40, 41 Similar attempts to define the relationship between exposure and effect of busulphan were reported. Spiro et al 42 investigated in vitro inhibition of colony formation of progenitor cells from normal and CML peripheral blood using a CFU-C assay, and calculated exposure (concentration ϫ time). The exposure that inhibited CFU-C formation by 90% in normal and CML progenitors was higher compared to what we found in the present study. However, the authors did not consider degradation of busulphan in the calculation of exposure in their study. In the present study, the decrease in survival of CFU-GM related to AUC is in good agreement with other reports when concentrations and times of incubation are recalculated as the AUC. 16, 18 However, while all previous studies used light density cells, CD34
+ progenitor cells were used in the present investigation. Our study was not designed to investigate the pharmacodynamic effect of busulphan on the very primitive hematopoietic progenitors. These progenitors are, as reported by many, more sensitive to busulphan than committed progenitors. We have chosen to study the CD34 + progenitors since their depletion is an important issue in SCT-related pancytopenia.
We found that CFU-GM were more sensitive to busulphan than erythroid colonies. This finding opposes the report of Kubota et al 17 that BFU-E (burst-forming unit erythroid) were more sensitive to busulphan compared to CFU-GM using light density cells from peripheral blood, and from bone marrow from both healthy volunteers and Bone Marrow Transplantation CML patients. However, our study differs from that of Kubota et al in the composition of growth factors used in colony formation assay. Moreover, studies in mice showed differential sensitivity of erythroid progenitors to busulphan with less sensitivity observed in the more mature cells. 15 Another investigation in rats found a higher sensitivity to busulphan in the granulocytic compared to the erythroid repopulating ability. 43 The myeloablative conditioning regimen aims to deplete the recipient of hematopoietic progenitors. Since high-dose therapy is also accompanied by severe toxicity to other organs, effective prophylactic measures decreasing conditioning-related toxicity could improve the overall outcome of transplantation. It is essential that such prophylactic treatment does not alter the effect of the cytotoxic drugs on the hematopoietic progenitors.
Veno-occlusive disease is one of the major complications related to conditioning regimens and glutathione depletion plays an important role in its pathophysiologic mechanism. Busulphan is metabolized in the liver through conjugation with GSH catalyzed by glutathione S-transferases (GST). Treatment with busulphan depleted GSH by about 50% in murine hepatocytes in vivo and in vitro, and increased cellular levels of GSH protected hepatocytes against busulphan-induced toxicity. 34 Recently, we have shown that patients receiving cyclophosphamide (Cy) less than 24 h after the last dose of busulphan had unfavorable pharmacokinetics of Cy and a higher risk of VOD compared to patients who were given Cy more than 24 h after the last dose of busulphan. Cyclophosphamide is an alkylating agent and its metabolites are detoxified through conjugation with GSH. We hypothesized that busulphan decreases the GSH content of hepatocytes which are subsequently damaged by toxic metabolites of Cy. 44 Thus, an increase in the cellular level of GSH may play an important role in the prophylactic treatment of VOD. However, it should not interact with myeloablative and anti-leukemic effects of busulphan.
In order to investigate the effect of modulation of cellular GSH on busulphan cytotoxicity in hematopoietic cells, we designed a study comprising three parallel systems, normal human bone marrow and a human leukemic cell line in vitro, and a mouse model in vivo. Increased intracellular levels of GSH did not affect busulphan-induced cytotoxicity in CD34 + progenitor cells in vitro. This has not previously been studied in hematopoietic progenitor cells, but N-acetylcysteine has been shown to protect CFU-GM from normal bone marrow against radiation. 45 Similarly, we could not demonstrate that NAC decreased busulphaninduced myelotoxicity in mice. Lack of protection of murine bone marrow cells in vivo by NAC was also reported for other drugs, such as cyclophosphamide, doxorubicin or cis-dichlorodiammineplatinum(II). 46, 47 To corroborate that GSH is not involved in busulphaninduced myelotoxicity we investigated the effect of GSH depletion by BSO on busulphan-induced cytototoxicity. GSH was depleted to 50% in CD34 + cells. This level of GSH should not induce endogenous oxidative stress in cells and only an additive effect to busulphan toxicity could be expected. However, no additive effect of BSO to busulphan-induced toxicity was observed in CD34
+ cells. Treat-ment of mice with BSO preceding the treatment with busulphan did not influence the myelosuppressive effect of busulphan within the time interval studied. GSH depletion is known to increase the effect of alkylating agents in many cell types and animal models and GSH depletion was shown to increase busulphan toxicity in hepatocytes in vitro. 27, 34 However, no additive effect to busulphan-induced growth delay and tumor regression in human glioblastoma multiforme xenografts was observed. 48 Modulation of GSH should not interfere with the antileukemic effect of conditioning regimens. Recently, we have reported the effect of busulphan on colony formation in the leukemic myeloid P39 cell line in vitro. 12 The inhibitory AUCs of the P39 cells (I-AUC 50 of 35.5 g.h/ml and I-AUC 100 of 148 g.h/ml) were similar to those observed in primary hematopoietic progenitors (Table 1) . Thus, the sensitivity of leukemic cells may be within the pharmacological therapeutic window of busulphan.
In the present study, we could not demonstrate any effect of increased GSH levels in the myeloid P39 cells on busulphan-induced cytotoxicity. However, some additive toxicity was observed when P39 cells were depleted in GSH and treated with busulphan, which is probably due to decreased protection against endogenous oxidative stress. The P39 cell line has similar sensitivity to busulphan as primary hematopoietic progenitor cells and thus studies of more resistant leukemic cells are warranted.
In conclusion, the pharmacodynamic effect of busulphan was linear in human CD34
+ progenitor cells as well as in a leukemic cell line. Modulation of GSH cellular content did not affect busulphan-induced cytotoxicity in hematopoietic stem cells, in a leukemic cell line or in mouse bone marrow. Thus N-acetylcysteine may serve as a prophylactic agent against the hepatotoxicity induced by busulphan. Our results are potentially of great clinical relevance and may promote N-acetylcysteine as a drug for VOD prophylaxis during busulphan-based conditioning regimens.
